Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Nina Zdinjak

EXCLUSIVE: Irwin Naturals CEO Explains Importance Of Brand In Booming Psychedelics Space

  • One of the challenges faced by the psychedelics industry is that trauma and mental illness are tied to income, yet off-label ketamine treatment is not yet covered by insurance, Klee Irwin, founder, CEO, & chairman of Irwin Naturals (OTC: IWINF) told the inaugural Benzinga Psychedelics Capital Conference on Tuesday.

    Is there a solution? The Power Of Brand 

    According to Irwin, “The solution is to use the power of brand to drive down patient costs.”

    Irwin Naturals is considered the world’s largest seller of CBD in the mass market, and this year it is extending its brand to psychedelics and THC. Irwin Natural’s nutraceutical products are sold in large outlets across America, including Costco (NASDAQ:COST), Walmart (NYSE:WMT), and Whole Foods. The brand seeks to make itself familiar to 80% of U.S. households. 

    “We intend to be the world's first truly household name brand, with a national and then international footprint in clinics,” added Irwin, explaining that 28-year run rate of profitability is enabling the company to have the “rare Coca-Cola (NYSE:KO) first-mover advantage.”

    Brands are important because consumers are not buying products or services, they are buying brands.

    Two Brand Classes

    There will be two brand classes in this disruptive industry of psychedelic mental health, according to Irwin. First – major drug brands, and second - major national clinic chain brands that employ doctors the pharmaceutical companies must go through to get their drugs into the hands of patients.

    “Building a household name brand is very expensive and it takes decades of presence in the market. But once a household name brand is established, operating costs can go down precipitously,” he noted, pointing out that lower operating expenses automatically are passed onto patients and third-party payers, so accessibility increases.

    The Potential Of The Psychedelics Industry

    How big is this opportunity?

    It seems that some 25% of adults have a diagnosable mental illness like insomnia, anxiety, subclinical PTSD, depression – all of whom could benefit from psychedelics treatment. This means that we need “a heck of a lot more than the 600 ketamine clinics.”

    Doing Good Above All

    For Irwin, doing good should come first. He called the mental health crisis scarier than the chance of nuclear holocaust. 

    “We need to take care of the people in our society who are suffering the most, and leveraging brand is the way to do it,” Irwin concluded. 

Photo: Courtesy of Nick Fewings on Unsplash

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.